RxDoctor Payments Data

Brenna Young

Family · Cleburne, TXNPI 1346828845

Payments from drug & device makers

$3,160in general payments, 2019–2025

Across 142 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$981
  • Abbott$597
  • Collegium Pharmaceutical, Inc.$243
  • Saluda Medical Americas, Inc.$214
  • AbbVie$207
  • Boehringer Ingelheim$164
  • plus $754 from 20 others

What the payments were for

  • Travel & lodging$31110%
  • Food & beverage$2,79488%
  • Education$542%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,160 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$87,411
Medicare patients
315
Services billed
856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl17$11,458
Buprenorphine37$10,301
Lidocaine13$3,438
Gabapentin253$3,090
Pregabalin152$2,443
Acetaminophen-CodeineAcetaminophen With Codeine115$2,034
Tramadol Hcl161$1,862
Tizanidine Hcl130$1,269
Methocarbamol88$1,113
Cyclobenzaprine Hcl101$1,067
Etodolac14$872
Duloxetine Hcl35$764
Diclofenac Sodium15$419
Celecoxib27$372
Baclofen20$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$243$11,45817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Cleburne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →